ArticleAnnals of medicine2026
Interpretable machine learning analysis of immune-inflammatory biomarkers for predicting no-reflow in patients with acute myocardial infarction after percutaneous coronary intervention.
Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate whether routine immune-inflammatory biomarkers predict no-reflow (NR) after percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI) patients, quantify their incremental predictive value over clinical variables, and build an interpretable peri-procedural prediction model.
methodsThis prospective cohort recruited 382 AMI patients undergoing PCI. Univariable and multivariable logistic regression identified independent correlates; confounder-adjusted restricted cubic splines (RCS) assessed nonlinear associations. LASSO regression selected core predictors with variance inflation factor (VIF) assessing multicollinearity. Four machine-learning models underwent 1000-iteration bootstrap internal validation and SHAP interpretation. Incremental value was tested via ΔAUC (DeLong test), continuous NRI, and IDI. Stratified regression and interaction tests evaluated AMI-subtype effect modification.
resultsNR occurred in 91 patients (23.8%). Multiple neutrophil-centred indices independently correlated with NR after adjustment. Seven predictors constituted the final model (all VIF < 2.5). LightGBM yielded optimal discrimination and modest net clinical benefit (AUC 0.799, 95% CI 0.699-0.899); AMI subtype and neutrophil-related markers dominated SHAP outputs. Neutrophil count, NAR, NHR, SII, and PIV significantly improved discrimination. Seven of the 16 tested markers yielded significant continuous NRI, and ten demonstrated significant IDI gains. In stratified analyses, neutrophil count, NLR, and MHR were associated with NR in STEMI but not NSTEMI patients; interaction tests found no significant AMI-subtype effect modification.
conclusionPre-procedural neutrophil-centred inflammatory biomarkers are independent correlates of post-PCI NR and offer incremental predictive value over conventional clinical variables. The interpretable LightGBM model supports peri-procedural NR risk stratification, though external validation and recalibration are mandatory before clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.